Pardes Biosciences Stock (NASDAQ:PRDS)
Previous Close
$2.16
52W Range
$0.75 - $3.67
50D Avg
$2.03
200D Avg
$1.70
Market Cap
$135.19M
Avg Vol (3M)
$509.69K
Beta
0.42
Div Yield
-
PRDS Company Profile
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
PRDS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| ACHL | Achilles Therapeutics plc |
| NXTC | NextCure, Inc. |
| IPSC | Century Therapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| ASMB | Assembly Biosciences, Inc. |
| OVID | Ovid Therapeutics Inc. |
| NLTX | Neurogene Inc. |
| TIL | Instil Bio, Inc. |
| STTK | Shattuck Labs, Inc. |
| ELYM | Eliem Therapeutics, Inc. |